Cover Image
市場調查報告書

前列腺癌:開發中產品分析

Prostate Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232770
出版日期 內容資訊 英文 1699 Pages
訂單完成後即時交付
價格
Back to Top
前列腺癌:開發中產品分析 Prostate Cancer - Pipeline Review, H2 2016
出版日期: 2016年12月21日 內容資訊: 英文 1699 Pages
簡介

前列腺癌是由於前列腺發病的癌症之一,男性,尤其是高齡的男性患病。主要的症狀有排尿時麻煩和力量低,血尿,腰、臀部、大腿部等的疼痛等。易罹病素質中包含年齡和家族病史,肥胖症等。主要的治療方法有外科手術和化療,放射治療等。

本報告提供全球各國的前列腺癌治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

簡介

前列腺癌概要

治療藥的開發

前列腺癌:企業開發中的治療藥

前列腺癌:大學/機關研究中的治療藥

前列腺癌:開發中產品概況

前列腺癌:企業開發中的產品

前列腺癌:大學/機關研究中的產品

前列腺癌的治療藥開發作的企業

前列腺癌:治療藥的評估

藥物簡介

前列腺癌:暫停中的計劃

前列腺癌:開發中止的產品

前列腺癌:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8860IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer - Pipeline Review, H2 2016, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prostate Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 91, 98, 4, 231, 32 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 10, 58 and 23 molecules, respectively.

Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Prostate Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Prostate Cancer Overview
  • Therapeutics Development
  • Prostate Cancer - Therapeutics under Development by Companies
  • Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
  • Prostate Cancer - Pipeline Products Glance
  • Prostate Cancer - Products under Development by Companies
  • Prostate Cancer - Products under Investigation by Universities/Institutes
  • Prostate Cancer - Companies Involved in Therapeutics Development
  • Prostate Cancer - Therapeutics Assessment
  • Drug Profiles
  • Prostate Cancer - Dormant Projects
  • Prostate Cancer - Discontinued Products
  • Prostate Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Prostate Cancer, H2 2016
  • Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Development by Companies, H2 2016 (Contd..11)
  • Number of Products under Development by Companies, H2 2016 (Contd..12)
  • Number of Products under Development by Companies, H2 2016 (Contd..13)
  • Number of Products under Development by Companies, H2 2016 (Contd..14)
  • Number of Products under Development by Companies, H2 2016 (Contd..15)
  • Number of Products under Development by Companies, H2 2016 (Contd..16)
  • Number of Products under Development by Companies, H2 2016 (Contd..17)
  • Number of Products under Development by Companies, H2 2016 (Contd..18)
  • Number of Products under Development by Companies, H2 2016 (Contd..19)
  • Number of Products under Development by Companies, H2 2016 (Contd..20)
  • Number of Products under Development by Companies, H2 2016 (Contd..21)
  • Number of Products under Development by Companies, H2 2016 (Contd..22)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Development by Companies, H2 2016 (Contd..20)
  • Products under Development by Companies, H2 2016 (Contd..21)
  • Products under Development by Companies, H2 2016 (Contd..22)
  • Products under Development by Companies, H2 2016 (Contd..23)
  • Products under Development by Companies, H2 2016 (Contd..24)
  • Products under Development by Companies, H2 2016 (Contd..25)
  • Products under Development by Companies, H2 2016 (Contd..26)
  • Products under Development by Companies, H2 2016 (Contd..27)
  • Products under Development by Companies, H2 2016 (Contd..28)
  • Products under Development by Companies, H2 2016 (Contd..29)
  • Products under Development by Companies, H2 2016 (Contd..30)
  • Products under Development by Companies, H2 2016 (Contd..31)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..5)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..6)
  • Prostate Cancer - Pipeline by 4SC AG, H2 2016
  • Prostate Cancer - Pipeline by AB Science SA, H2 2016
  • Prostate Cancer - Pipeline by AbbVie Inc, H2 2016
  • Prostate Cancer - Pipeline by Actinium Pharmaceuticals Inc, H2 2016
  • Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corp, H2 2016
  • Prostate Cancer - Pipeline by ADC Therapeutics Sarl, H2 2016
  • Prostate Cancer - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Prostate Cancer - Pipeline by Aduro BioTech Inc, H2 2016
  • Prostate Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2016
  • Prostate Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016
  • Prostate Cancer - Pipeline by Advantagene Inc, H2 2016
  • Prostate Cancer - Pipeline by Advaxis Inc, H2 2016
  • Prostate Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2016
  • Prostate Cancer - Pipeline by Aeolus Pharmaceuticals Inc, H2 2016
  • Prostate Cancer - Pipeline by Aeterna Zentaris Inc, H2 2016
  • Prostate Cancer - Pipeline by Aileron Therapeutics Inc, H2 2016
  • Prostate Cancer - Pipeline by Akshaya Bio Inc, H2 2016
  • Prostate Cancer - Pipeline by Alchemia Ltd, H2 2016
  • Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2016
  • Prostate Cancer - Pipeline by Alissa Pharma, H2 2016
  • Prostate Cancer - Pipeline by Almac Discovery Ltd, H2 2016
  • Prostate Cancer - Pipeline by Ambrx Inc, H2 2016
  • Prostate Cancer - Pipeline by American Gene Technologies International Inc, H2 2016
  • Prostate Cancer - Pipeline by Amgen Inc, H2 2016
  • Prostate Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016
  • Prostate Cancer - Pipeline by AndroScience Corp, H2 2016
  • Prostate Cancer - Pipeline by AnGes MG Inc, H2 2016
  • Prostate Cancer - Pipeline by AntiCancer Inc, H2 2016
  • Prostate Cancer - Pipeline by Antigen Express Inc, H2 2016
  • Prostate Cancer - Pipeline by Antisense Therapeutics Ltd, H2 2016
  • Prostate Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016
  • Prostate Cancer - Pipeline by Apcure SAS, H2 2016
  • Prostate Cancer - Pipeline by Aphios Corp, H2 2016
  • Prostate Cancer - Pipeline by APIM Therapeutics AS, H2 2016
  • Prostate Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016
  • Prostate Cancer - Pipeline by Aptose Biosciences Inc, H2 2016
  • Prostate Cancer - Pipeline by ARMO Biosciences Inc, H2 2016
  • Prostate Cancer - Pipeline by Armour Therapeutics Inc, H2 2016
  • Prostate Cancer - Pipeline by Arno Therapeutics Inc, H2 2016
  • Prostate Cancer - Pipeline by ArQule Inc, H2 2016
  • Prostate Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016
  • Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016
  • Prostate Cancer - Pipeline by Arvinas Inc, H2 2016
  • Prostate Cancer - Pipeline by Asana BioSciences LLC, H2 2016
  • Prostate Cancer - Pipeline by Astellas Pharma Inc, H2 2016
  • Prostate Cancer - Pipeline by Asterias Biotherapeutics Inc, H2 2016
  • Prostate Cancer - Pipeline by AstraZeneca Plc, H2 2016
  • Prostate Cancer - Pipeline by ATLAB Pharma SAS, H2 2016
  • Prostate Cancer - Pipeline by Aura Biosciences Inc, H2 2016
  • Prostate Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016
  • Prostate Cancer - Pipeline by Avipep Pty Ltd, H2 2016
  • Prostate Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016
  • Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2016
  • Prostate Cancer - Pipeline by Bayer AG, H2 2016
  • Prostate Cancer - Pipeline by BeiGene Ltd, H2 2016
  • Prostate Cancer - Pipeline by Bexion Pharmaceuticals LLC, H2 2016
  • Prostate Cancer - Pipeline by BHR Pharma LLC, H2 2016
  • Prostate Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016
  • Prostate Cancer - Pipeline by Biotest AG, H2 2016
  • Prostate Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H2 2016
  • Prostate Cancer - Pipeline by Blirt SA, H2 2016
  • Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Prostate Cancer - Pipeline by Camurus AB, H2 2016
  • Prostate Cancer - Pipeline by Can-Fite BioPharma Ltd, H2 2016
  • Prostate Cancer - Pipeline by CEL-SCI Corp, H2 2016
  • Prostate Cancer - Pipeline by Celgene Corp, H2 2016
  • Prostate Cancer - Pipeline by CellCentric Ltd, H2 2016
  • Prostate Cancer - Pipeline by Cellceutix Corp, H2 2016
  • Prostate Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016
  • Prostate Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016
  • Prostate Cancer - Pipeline by Cellmid Ltd, H2 2016
  • Prostate Cancer - Pipeline by Celprogen Inc, H2 2016
  • Prostate Cancer - Pipeline by Chamaeleo Pharma NV, H2 2016
  • Prostate Cancer - Pipeline by Chiome Bioscience Inc, H2 2016
  • Prostate Cancer - Pipeline by Clovis Oncology Inc, H2 2016
  • Prostate Cancer - Pipeline by CohBar Inc, H2 2016
  • Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H2 2016
  • Prostate Cancer - Pipeline by Corcept Therapeutics Inc, H2 2016
  • Prostate Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016
  • Prostate Cancer - Pipeline by Crescendo Biologics Ltd, H2 2016
  • Prostate Cancer - Pipeline by Curevac AG, H2 2016
  • Prostate Cancer - Pipeline by CytoVac A/S, H2 2016
  • Prostate Cancer - Pipeline by CZ BioMed Corp, H2 2016
  • Prostate Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016
  • Prostate Cancer - Pipeline by DEKK-TEC Inc, H2 2016
  • Prostate Cancer - Pipeline by DexTech Medical AB, H2 2016
  • Prostate Cancer - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016
  • Prostate Cancer - Pipeline by DNJ Pharma Inc, H2 2016
  • Prostate Cancer - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2016
  • Prostate Cancer - Pipeline by DormaTarg Inc, H2 2016
  • Prostate Cancer - Pipeline by Eisai Co Ltd, H2 2016
  • Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2016
  • Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H2 2016
  • Prostate Cancer - Pipeline by EndoCeutics Inc, H2 2016
  • Prostate Cancer - Pipeline by Endocyte Inc, H2 2016
  • Prostate Cancer - Pipeline by EntreChem SL, H2 2016
  • Prostate Cancer - Pipeline by EOS Biosciences Inc, H2 2016
  • Prostate Cancer - Pipeline by Errant Gene Therapeutics LLC, H2 2016
  • Prostate Cancer - Pipeline by Esperance Pharmaceuticals Inc, H2 2016
  • Prostate Cancer - Pipeline by ESSA Pharma Inc, H2 2016
  • Prostate Cancer - Pipeline by Eureka Therapeutics Inc, H2 2016
  • Prostate Cancer - Pipeline by Evgen Pharma Plc, H2 2016
  • Prostate Cancer - Pipeline by Exonate Ltd, H2 2016
  • Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Prostate Cancer - Pipeline by Ferring International Center SA, H2 2016
  • Prostate Cancer - Pipeline by Foresee Pharmaceuticals LLC, H2 2016
  • Prostate Cancer - Pipeline by Fountain Biopharma Inc, H2 2016
  • Prostate Cancer - Pipeline by Fujifilm Corp, H2 2016
  • Prostate Cancer - Pipeline by G1 Therapeutics Inc, H2 2016
  • Prostate Cancer - Pipeline by Galectin Therapeutics Inc, H2 2016
  • Prostate Cancer - Pipeline by Genelux Corp, H2 2016
  • Prostate Cancer - Pipeline by Genentech Inc, H2 2016
  • Prostate Cancer - Pipeline by GeneSegues Inc, H2 2016
  • Prostate Cancer - Pipeline by Genmab A/S, H2 2016
  • Prostate Cancer - Pipeline by Gilead Sciences Inc, H2 2016
  • Prostate Cancer - Pipeline by Glactone Pharma AB, H2 2016
  • Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Prostate Cancer - Pipeline by GlycoMimetics Inc, H2 2016
  • Prostate Cancer - Pipeline by GP Pharm SA, H2 2016
  • Prostate Cancer - Pipeline by GTx Inc, H2 2016
  • Prostate Cancer - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016
  • Prostate Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016
  • Prostate Cancer - Pipeline by Health Ever Bio-Tech Co Ltd, H2 2016
  • Prostate Cancer - Pipeline by Hybrigenics SA, H2 2016
  • Prostate Cancer - Pipeline by IC-MedTech Inc, H2 2016
  • Prostate Cancer - Pipeline by Ideaya Biosciences Inc, H2 2016
  • Prostate Cancer - Pipeline by IGF Oncology LLC, H2 2016
  • Prostate Cancer - Pipeline by Ignyta Inc, H2 2016
  • Prostate Cancer - Pipeline by Ildong Pharmaceutical Co Ltd, H2 2016
  • Prostate Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2016
  • Prostate Cancer - Pipeline by Immuneed AB, H2 2016
  • Prostate Cancer - Pipeline by Immunocore Ltd, H2 2016
  • Prostate Cancer - Pipeline by ImmunoFrontier Inc, H2 2016
  • Prostate Cancer - Pipeline by Immunomedics Inc, H2 2016
  • Prostate Cancer - Pipeline by Immupharma Plc, H2 2016
  • Prostate Cancer - Pipeline by Incanthera Ltd, H2 2016
  • Prostate Cancer - Pipeline by Incuron LLC, H2 2016
  • Prostate Cancer - Pipeline by Inflection Biosciences Ltd, H2 2016
  • Prostate Cancer - Pipeline by Innate Immunotherapeutics Ltd, H2 2016

List of Figures

  • Number of Products under Development for Prostate Cancer, H2 2016
  • Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top